Martin Schiller

Martin R. Schiller, Ph.D. holds a B.S. in Biochemistry from Hofstra University and a Ph.D. in Biochemistry from Utah State University. Following three postdoctoral fellowships, he joined the faculty at the Johns Hopkins University School of Medicine and later the University of Connecticut, where he focused on peptide prohormones.

Dr. Schiller is currently the Prabhu Endowed Professor at the University of Nevada, Las Vegas (UNLV), and the founding director of the Nevada Institute of Personalized Medicine, established in 2015. His research spans functional genomics, bioinformatics, and biologics discovery. He has developed a suite of widely used bioinformatic tools, authored 90 peer-reviewed publications, and secured 27 research grants totaling approximately $31 million in NIH funding.

In addition to his academic accomplishments, Dr. Schiller founded Heligenics Inc., one of Las Vegas’s pioneering biotech startups. Heligenics is focused on creating Mutational Effect on Gene Activity (MEGA)-Maps to design novel companion diagnostics and biologic therapies. The company’s flagship technology, the GigaAssay—developed in Dr. Schiller’s lab—is the first platform capable of enabling High Content Screening for biologic drugs. This breakthrough has been instrumental in advancing multiple interferon-based drug candidates currently in development.